| Code | CSB-RA836186MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Unasnemab, designed for research applications targeting Repulsive Guidance Molecule A (RGMA). RGMA is a glycosylphosphatidylinositol-anchored protein that plays a critical role in axonal guidance during neural development and acts as an inhibitor of neuronal regeneration in the adult central nervous system. By binding to its receptor Neogenin, RGMA contributes to growth cone collapse and inhibits axonal outgrowth. This protein has been implicated in various neurological conditions, including spinal cord injury, stroke, and multiple sclerosis, where it limits neural repair and functional recovery. Elevated RGMA expression has also been associated with iron metabolism dysregulation and inflammatory processes in neurodegenerative diseases.
Unasnemab represents a therapeutic antibody developed to neutralize RGMA activity and promote neural regeneration. This biosimilar antibody provides researchers with a valuable tool for investigating RGMA-mediated signaling pathways, studying mechanisms of axonal inhibition, and exploring potential neuroprotective strategies in preclinical models of central nervous system injury and disease.
There are currently no reviews for this product.